Compare CSTL & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | BLMN |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 586.3M |
| IPO Year | 2019 | 2012 |
| Metric | CSTL | BLMN |
|---|---|---|
| Price | $38.83 | $6.76 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 7 |
| Target Price | ★ $38.67 | $8.29 |
| AVG Volume (30 Days) | 439.7K | ★ 2.3M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 10.22% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $343,530,000.00 | ★ $3,952,793,000.00 |
| Revenue This Year | $1.69 | $2.19 |
| Revenue Next Year | N/A | $0.32 |
| P/E Ratio | ★ N/A | $18.12 |
| Revenue Growth | ★ 10.15 | 7.72 |
| 52 Week Low | $14.59 | $5.90 |
| 52 Week High | $40.61 | $13.25 |
| Indicator | CSTL | BLMN |
|---|---|---|
| Relative Strength Index (RSI) | 71.92 | 48.57 |
| Support Level | $38.69 | $6.58 |
| Resistance Level | $40.54 | $6.93 |
| Average True Range (ATR) | 1.58 | 0.33 |
| MACD | -0.18 | 0.05 |
| Stochastic Oscillator | 75.59 | 62.88 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.